Patents

The Unitary Patent system is doing much better than expected, with almost 80 cases in the first six months and about 20-25% of new European patents converted to UPs, according to Paul England. He is…

A recent letter by the EPO's Central Staff Committee (CSC) about Rewarding quality in the core business is too important and far too well-written to remain unnoticed. Perhaps unsurprisingly, it…

The Status Quo injunction is not a variation on Wayne’s World classic “No Stairway, Denied” joke. While some may yearn for a ban on their generic tunes,  Status Quo is still not denied. That is not…

The EPO has proposed new amendments to the Rules of Procedure of the Boards of Appeal (RPBA) to support more ambitious timeliness objectives. In our view, they are unlikely to shorten appeal…

It will be nothing new for regular readers of this blog that I and many others have long been advocating for more well-qualified examiners at the EPO, e.g. here. Obviously, these examiners also need…

As with many other jurisdictions the fight over Novartis’ contested Fingolimod-patent (EP 2 959 894) (the “patent-in-suit”) is raging on in Denmark. Two recent cases from June and July yielded…

On 23 June 2023, the Madrid Appeal Court (Section 32) published one of the most interesting judgments coming from Spanish courts during the last few years. The first point of interest is that this is…

The flurry of opt-outs during the sunrise period of the Unified Patent Court was partly driven out of concern of potential central revocation actions being filed as soon as the Court opened. As it…

Introduction On 17 July 2023, the English Court of Appeal handed down its decision in a dispute between J.C. Bamford (JCB) and Manitou about the confidentiality of information disclosed in the…